Chemiluminescence assay of in vivo inflammation
US5108899A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Oct 31, 1989 |
| Grant date | Apr 28, 1992 |
| Priority date | — |
| Expiry date | Oct 31, 2009 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/975
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The presence or amount of in vivo inflammation of a patient is determined by comparing the extent of opsonin receptor expression in vivo on phagocytes of a patient with the maximum opsonin receptor expression inducible on phagocytes of the patient in vitro after stimulation with a receptor expression priming agent. Preferably, the in vivo state of inflammation of a patient is determined by contacting a first portion of a phagocyte containing biological sample from the patient with a opsonified oxidative metabolism stimulating agent capable of elicting metabolic activation and with a chemiluminigenic substrate, contacting a second portion of the biological sample from the patient with an opsonin receptor expression priming agent, an opsonfield oxidative metabolism stimulating agent capable of eliciting metabolic activation and a chemiluminigenic substrate, and then comparing the chemiluminescence response of the first and second portions of the sample as a measure of the immune response potential or state of inflammation of the patient. Phagocyte function is additionally quantitatively evaluated by measuring the phagocyte oxygenation capacity of a maximally opsonin receptor primed a…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.